Commit To Buy Soleno Therapeutics At $30, Earn 20.1% Annualized Using Options

Selling the June 2026 $30 put on Soleno Therapeutics (SLNO) offers a $3.50 premium for an implied 20.1% annualized return, but the seller only acquires shares if SLNO falls about 36.4% to the $30 strike—which would produce a pre-commission cost basis of $26.50. With shares trading at $47.38 and trailing 12‑month volatility at 73%, the trade delivers attractive income if unassigned but carries substantial downside and assignment risk, so its attractiveness depends on whether that premium compensates for the high volatility and the investor’s fundamental view of the company.

Analysis

Selling the June 2026 $30 put on Soleno Therapeutics (SLNO) yields a $3.50 premium, which the article calculates as a 20.1% annualized return. The contract would only be exercised if the stock falls roughly 36.4% from today's $47.38 to the $30 strike, producing a pre-commission cost basis of $26.50 per share (strike minus premium).

The piece notes trailing 12-month volatility of 73% (based on the last 250 trading days and today’s price), indicating elevated price dispersion and meaningful assignment risk relative to the income received. The put seller captures the premium if unassigned but gives up upside participation and only benefits from owning shares if the option is exercised at or below the strike.

Attractive nominal yield must be weighed against high realized volatility and the investor’s fundamental view of Soleno; the article and accompanying signals label sentiment as mixed with a cautious tone. Investors should therefore treat the trade as an income-for-assignment-risk decision and compare alternative expirations/strikes before committing.

Key Decisions for Investors

• Only sell the June 2026 $30 put if you are willing to be assigned and to own SLNO at a pre-commission cost basis of $26.50
• If you are not prepared to own shares at that level, avoid selling the put despite the 20.1% annualized premium
• Size the position conservatively and monitor trailing volatility (73%) and price moves toward $30 so assignment exposure remains acceptable
• Compare alternative expirations and strikes and reassess the trade if market sentiment or company fundamentals change from the current mixed, cautious backdrop